Table 3.

Comparison of OS between the simple chemotherapy and gefitinib groups

		Simple chemotherapy MST ( month) 95% CI	Gefitinib MST (mon) 95% CI	HR (95% CI)	P value
Age (year)	<60	14.1 (11.4–16.8)	33.5 (30.9–36.1)	0.290 (0.229–0.367)	<0.001
	≥60	13.0 (10.5–15.4)	33.5 (28.0–39.0)	0.348 (0.256–0.475)	<0.001
Gender	Male	14.2 (10.2–18.2)	33.0 (30.2–35.8)	0.363 (0.273–0.481)	<0.001
	Female	14.1 (12.2–16.0)	33.9 (30.5–37.3)	0.273 (0.212–0.352)	<0.001
Smoking history	No	14.6 (12.5–16.7)	35.5 (32.0–39.0)	0.332 (0.269–0.411)	<0.001
	Yes	9.9 (8.4–11.3)	30.0 (26.3–33.7)	0.228 (0.151–0.346)	<0.001
ECOG PS	0–1	14.2 (12.4–16.0)	34.0 (31.4–36.6)	0.310 (0.256–0.376)	<0.001
	≥2	9.2 (7.2–11.2)	19.5 (6.0–32.9)	0.490 (0.215–1.117)	0.090
Stage	IIIB	8.3 (6.6–9.9)	35.7 (31.8–39.6)	0.093 (0.035–0.248)	<0.001
	IV	14.5 (12.4–16.6)	33.5 (31.1–35.9)	0.331 (0.273–0.402)	<0.001
Organ metastasis	No	12.8 (10.9–14.7)	32.0 (27.4–36.6)	0.323 (0.249–0.418)	<0.001
	Yes	16.2 (13.4–18.9)	34.0 (29.7–38.2)	0.327 (0.248–0.430)	<0.001
Pleural	No	14.1 (12.2–16.1)	33.5 (30.5–36.6)	0.263 (0.202–0.342)	<0.001
	Yes	14.4 (11.6–17.3)	33.0 (29.5–36.4)	0.374 (0.285–0.490)	<0.001
Bone	No	15.5 (12.0–18.9)	33.9 (31.1–36.7)	0.332 (0.264–0.418)	<0.001
	Yes	12.3 (10.7–13.9)	32.4 (25.5–39.2)	0.304 (0.220–0.420)	<0.001
Brain	No	12.7 (10.9–14.6)	34.0 (31.1–36.9)	0.282 (0.227–0.352)	<0.001
	Yes	16.4 (11.8–21.0)	31.5 (28.8–34.2)	0.416 (0.288–0.600)	<0.001
Adrenal gland	No	14.4 (12.2–16.7)	34.0 (31.5–36.5)	0.312 (0.258–0.378)	<0.001
	Yes	12.0 (7.7–16.3)	21.0 (11.7–30.3)	0.397 (0.164–0.960)	0.040
Liver	No	14.5 (12.3–16.6)	33.5 (31.0–36.0)	0.325 (0.268–0.395)	<0.001
	Yes	12.2 (9.8–14.5)	30.8 (3.2–58.4)	0.234 (0.107–0.514)	<0.001
Prior chemo	1–2	10.6 (9.5–11.8)	33.0 (31.3–34.8)	0.190 (0.152–0.238)	<0.001
	≥3	27.3 (25.0–29.6)	40.5 (27.6–53.3)	0.406 (0.252–0.653)	<0.001

CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; OS, overall survival; PS, performance status.